DB05224ExperimentalSmall molecule
REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
- Mechanism
- Curator reviewed
REP8839 exerts its antibacterial activity through specific inhibition of MetS, a novel target.
- Primary indication
- For the treatment of bacterial infections caused by susceptible microorganisms (Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA), and Streptococcus pyogenes).Curator reviewed
- Code names
- REP8839
Resolves to
Compound
Targets
What you can answer from here — as of April 02, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with REP8839, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account